TMR's report on the global drug-eluting stents market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global drug-eluting stents market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global drug-eluting stents market from 2025 to 2035.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the drug-eluting stents market.
Market Snapshot
Market Value in 2024
US$ 7.7 Bn
Market Value in 2035
US$ 14.2 Bn
CAGR
5.7%
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global drug-eluting stents market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global drug-eluting stents market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global drug-eluting stents market.
The report delves into the competitive landscape of the global drug-eluting stents market. Key players operating in the global drug-eluting stents market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global drug-eluting stents market profiled in this report.
Key Questions Answered in global drug-eluting stents Market Report:
What is the sales/revenue generated by drug-eluting stents across all regions during the forecast period?
What are the opportunities in the global drug-eluting stents market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2035?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Drug-Eluting Stents Market - Research Objectives and Research Approach
The comprehensive report on the global drug-eluting stents market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global drug-eluting stents market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global drug-eluting stents market.
Table of Contents
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Drug-Eluting Stents Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Drug-Eluting Stents Market Analysis and Forecast, 2020-2035
4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
5.1. Technological Advancements
5.2. PORTER's Five Forces Analysis
5.3. PESTEL Analysis
5.4. Supply Chain Analysis
5.5. Key Industry Events (Mergers, Acquisitions, Partnerships, Collaborations, etc.)
5.6. Pricing Analysis (Brand pricing, Average Selling Price by Region/Country)
5.7. Regulatory Scenario by Key Country/Region
5.8. Research and Development Trends
5.9. Go-to-Market Strategy for New Market Entrants
6. Global Drug-Eluting Stents Market Analysis and Forecast, by Material
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Material, 2020-2035
6.3.1. Metal
6.3.1.1. Stainless-Steel
6.3.1.2. Cobalt-Chromium
6.3.1.3. Nitinol
6.3.1.4. Others
6.3.2. Polymer
6.3.2.1. Non-biodegradable Polymers
6.3.2.2. Biodegradable Polymers
6.4. Market Attractiveness Analysis, by Material
7. Global Drug-Eluting Stents Market Analysis and Forecast, by Drug
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Drug, 2020-2035
7.3.1. Sirolimus
7.3.2. Paclitaxel
7.3.3. Zotarolimus
7.3.4. Everolimus
7.3.5. Others
7.4. Market Attractiveness Analysis, by Drug
8. Global Drug-Eluting Stents Market Analysis and Forecast, by Application
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Application , 2020-2035
8.3.1. Coronary Artery Disease
8.3.2. Peripheral Artery Disease
8.3.3. Others
8.4. Market Attractiveness Analysis, by Application
9. Global Drug-Eluting Stents Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2020-2035
9.3.1. Hospitals
9.3.2. Ambulatory Surgical Centers
9.3.3. Others
9.4. Market Attractiveness Analysis, by End-user
10. Global Drug-Eluting Stents Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020-2035
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Region
11. North America Drug-Eluting Stents Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Material, 2020-2035
11.2.1. Metal
11.2.1.1. Stainless-Steel
11.2.1.2. Cobalt-Chromium
11.2.1.3. Nitinol
11.2.1.4. Others
11.2.2. Polymer
11.2.2.1. Non-biodegradable Polymers
11.2.2.2. Biodegradable Polymers
11.3. Market Value Forecast, by Drug, 2020-2035
11.3.1. Sirolimus
11.3.2. Paclitaxel
11.3.3. Zotarolimus
11.3.4. Everolimus
11.3.5. Others
11.4. Market Value Forecast, by Application , 2020-2035
11.4.1. Coronary Artery Disease
11.4.2. Peripheral Artery Disease
11.4.3. Others
11.5. Market Value Forecast, by End-user, 2020-2035
11.5.1. Hospitals
11.5.2. Ambulatory Surgical Centers
11.5.3. Others
11.6. Market Value Forecast, by Country, 2020-2035
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Material
11.7.2. By Drug
11.7.3. By Application
11.7.4. By End-user
11.7.5. By Country
12. Europe Drug-Eluting Stents Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Material, 2020-2035
12.2.1. Metal
12.2.1.1. Stainless-Steel
12.2.1.2. Cobalt-Chromium
12.2.1.3. Nitinol
12.2.1.4. Others
12.2.2. Polymer
12.2.2.1. Non-biodegradable Polymers
12.2.2.2. Biodegradable Polymers
12.3. Market Value Forecast, by Drug, 2020-2035
12.3.1. Sirolimus
12.3.2. Paclitaxel
12.3.3. Zotarolimus
12.3.4. Everolimus
12.3.5. Others
12.4. Market Value Forecast, by Application , 2020-2035
12.4.1. Coronary Artery Disease
12.4.2. Peripheral Artery Disease
12.4.3. Others
12.5. Market Value Forecast, by End-user, 2020-2035
12.5.1. Hospitals
12.5.2. Ambulatory Surgical Centers
12.5.3. Others
12.6. Market Value Forecast, by Country/Sub-region, 2020-2035
12.6.1. Germany
12.6.2. UK
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Material
12.7.2. By Drug
12.7.3. By Application
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Drug-Eluting Stents Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Material, 2020-2035
13.2.1. Metal
13.2.1.1. Stainless-Steel
13.2.1.2. Cobalt-Chromium
13.2.1.3. Nitinol
13.2.1.4. Others
13.2.2. Polymer
13.2.2.1. Non-biodegradable Polymers
13.2.2.2. Biodegradable Polymers
13.3. Market Value Forecast, by Drug, 2020-2035
13.3.1. Sirolimus
13.3.2. Paclitaxel
13.3.3. Zotarolimus
13.3.4. Everolimus
13.3.5. Others
13.4. Market Value Forecast, by Application , 2020-2035
13.4.1. Coronary Artery Disease
13.4.2. Peripheral Artery Disease
13.4.3. Others
13.5. Market Value Forecast, by End-user, 2020-2035
13.5.1. Hospitals
13.5.2. Ambulatory Surgical Centers
13.5.3. Others
13.6. Market Value Forecast, by Country/Sub-region, 2020-2035
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Material
13.7.2. By Drug
13.7.3. By Application
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Drug-Eluting Stents Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Material, 2020-2035
14.2.1. Metal
14.2.1.1. Stainless-Steel
14.2.1.2. Cobalt-Chromium
14.2.1.3. Nitinol
14.2.1.4. Others
14.2.2. Polymer
14.2.2.1. Non-biodegradable Polymers
14.2.2.2. Biodegradable Polymers
14.3. Market Value Forecast, by Drug, 2020-2035
14.3.1. Sirolimus
14.3.2. Paclitaxel
14.3.3. Zotarolimus
14.3.4. Everolimus
14.3.5. Others
14.4. Market Value Forecast, by Application , 2020-2035
14.4.1. Coronary Artery Disease
14.4.2. Peripheral Artery Disease
14.4.3. Others
14.5. Market Value Forecast, by End-user, 2020-2035
14.5.1. Hospitals
14.5.2. Ambulatory Surgical Centers
14.5.3. Others
14.6. Market Value Forecast, by Country/Sub-region, 2020-2035
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Material
14.7.2. By Drug
14.7.3. By Application
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Drug-Eluting Stents Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Material, 2020-2035
15.2.1. Metal
15.2.1.1. Stainless-Steel
15.2.1.2. Cobalt-Chromium
15.2.1.3. Nitinol
15.2.1.4. Others
15.2.2. Polymer
15.2.2.1. Non-biodegradable Polymers
15.2.2.2. Biodegradable Polymers
15.3. Market Value Forecast, by Drug, 2020-2035
15.3.1. Sirolimus
15.3.2. Paclitaxel
15.3.3. Zotarolimus
15.3.4. Everolimus
15.3.5. Others
15.4. Market Value Forecast, by Application , 2020-2035
15.4.1. Coronary Artery Disease
15.4.2. Peripheral Artery Disease
15.4.3. Others
15.5. Market Value Forecast, by End-user, 2020-2035
15.5.1. Hospitals
15.5.2. Ambulatory Surgical Centers
15.5.3. Others
15.6. Market Value Forecast, by Country/Sub-region, 2020-2035
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Material
15.7.2. By Drug
15.7.3. By Application
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2024)
16.3. Company Profiles
16.3.1. Abbott Laboratories
16.3.1.1. Company Overview
16.3.1.2. Financial Overview
16.3.1.3. Product Portfolio
16.3.1.4. Business Strategies
16.3.1.5. Recent Developments
16.3.2. AlviMedica
16.3.2.1. Company Overview
16.3.2.2. Financial Overview
16.3.2.3. Product Portfolio
16.3.2.4. Business Strategies
16.3.2.5. Recent Developments
16.3.3. B. Braun Melsungen AG
16.3.3.1. Company Overview
16.3.3.2. Financial Overview
16.3.3.3. Product Portfolio
16.3.3.4. Business Strategies
16.3.3.5. Recent Developments
16.3.4. Biosensors International Group, Ltd.
16.3.4.1. Company Overview
16.3.4.2. Financial Overview
16.3.4.3. Product Portfolio
16.3.4.4. Business Strategies
16.3.4.5. Recent Developments
16.3.5. Shandong JW Medical Systems LTD.
16.3.5.1. Company Overview
16.3.5.2. Financial Overview
16.3.5.3. Product Portfolio
16.3.5.4. Business Strategies
16.3.5.5. Recent Developments
16.3.6. Boston Scientific Corporation
16.3.6.1. Company Overview
16.3.6.2. Financial Overview
16.3.6.3. Product Portfolio
16.3.6.4. Business Strategies
16.3.6.5. Recent Developments
16.3.7. Cook Medical Inc.
16.3.7.1. Company Overview
16.3.7.2. Financial Overview
16.3.7.3. Product Portfolio
16.3.7.4. Business Strategies
16.3.7.5. Recent Developments
16.3.8. Elixir Medical Corp.
16.3.8.1. Company Overview
16.3.8.2. Financial Overview
16.3.8.3. Product Portfolio
16.3.8.4. Business Strategies
16.3.8.5. Recent Developments
16.3.9. Lepu Medical Technology (Beijing) Co., Ltd.